Edition:
United Kingdom

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

43.93USD
6:30pm BST
Change (% chg)

$0.15 (+0.34%)
Prev Close
$43.78
Open
$43.76
Day's High
$44.10
Day's Low
$43.53
Volume
33,281
Avg. Vol
202,806
52-wk High
$60.98
52-wk Low
$36.19

Latest Key Developments (Source: Significant Developments)

Esperion To Present Final Results Of Bempedoic Acid Pivotal Phase 3 Study 2
Monday, 18 Mar 2019 

March 18 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES LATE-BREAKING PRESENTATION OF FINAL RESULTS OF BEMPEDOIC ACID PIVOTAL PHASE 3 STUDY 2 AT THE AMERICAN COLLEGE OF CARDIOLOGY 2019 SCIENTIFIC SESSIONS.ESPERION THERAPEUTICS INC - STUDY 2 DEMONSTRATED BEMPEDOIC ACID SIGNIFICANTLY LOWERED LDL-CHOLESTEROL AND REDUCED HSCRP.ESPERION - OVER 52-WEEKS, BEMPEDOIC ACID WAS OBSERVED TO BE SAFE, WELL-TOLERATED, AND ADVERSE EVENT PROFILE WAS SIMILAR TO THAT OF PLACEBO.  Full Article

Esperion Provides Bempedoic Acid Franchise Development Program Updates, Reports Fourth Quarter Results
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Esperion Therapeutics Inc ::ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.ESPERION THERAPEUTICS INC - ESPERION EXPECTS 2019 NET CASH USED IN OPERATIONS TO BE $25 TO $35 MILLION.ESPERION THERAPEUTICS INC - QTRLY LOSS PER SHARE $2.24.  Full Article

Esperion Announces '+ve' Top-Line Results From Pivotal Phase 3 Ezetimibe Combination Pill Study
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 BEMPEDOIC ACID / EZETIMIBE COMBINATION PILL STUDY.BEMPEDOIC ACID / EZETIMIBE COMBO PILL APPEARED TO BE AS SAFE AND WELL-TOLERATED AS EZETIMIBE ALONE.NO SAES WERE CONSIDERED TO BE RELATED TO STUDY MEDICATION.TOPLINE DATA FROM STUDY 2 (1002-047) ARE NOW EXPECTED IN OCTOBER 2018.NDAS WILL BE SUBMITTED DURING Q1 OF 2019..TOPLINE DATA FROM STUDY 2 (1002-047) ARE NOW EXPECTED IN OCTOBER 2018.POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 BEMPEDOIC ACID / EZETIMIBE COMBINATION PILL STUDY (1002-053).  Full Article

Esperion Posts Qtrly Loss Per Share $1.73
Wednesday, 2 May 2018 

May 2 (Reuters) - Esperion Therapeutics Inc ::ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.ESPERION THERAPEUTICS INC - EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE APPROXIMATELY $135 TO $145 MILLION.ESPERION THERAPEUTICS - ESTIMATES THAT CURRENT CASH RESOURCES ARE SUFFICIENT TO FUND OPERATIONS THROUGH Q1 OF 2020.ESPERION THERAPEUTICS INC - EXPECTS CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE APPROXIMATELY $130 TO $140 MILLION AT DECEMBER 31, 2018.ESPERION THERAPEUTICS INC QTRLY LOSS PER SHARE $1.73.  Full Article

Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint
Wednesday, 2 May 2018 

May 2 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 LONG-TERM SAFETY STUDY OF BEMPEDOIC ACID.ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY IN LARGEST AND LONGEST DURATION STUDY.ESPERION - PATIENTS TREATED WITH BEMPEDOIC ACID ALSO ACHIEVED A SIGNIFICANT REDUCTION OF 22 PERCENT IN HIGH-SENSITIVITY C-REACTIVE PROTEIN.  Full Article

Esperion Announces Positive Top-Line Results From Phase 2 Study Of Bempedoic Acid Added-On To A PCSK9 Inhibitor
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR IN PATIENTS WITH HYPERCHOLESTEROLEMIA.ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT WITH 30% ADDITIONAL LDL-C LOWERING.ESPERION THERAPEUTICS INC - BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR OBSERVED TO BE SAFE AND WELL-TOLERATED IN THIS STUDY.ESPERION THERAPEUTICS - TO SUBMIT NDAS TO U.S. FDA FOR BEMPEDOIC ACID, BEMPEDOIC ACID/EZETIMIBE COMBINATION PILL FOR LDL-C-LOWERING INDICATIONS BY Q1 2019.  Full Article

Esperion Therapeutics Q3 loss per share $1.86‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Esperion Therapeutics Inc :Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results.Expects full-year 2017 net cash used in operating activities to be approximately $135 million​.Expects cash and cash equivalents and investment securities to be approximately $272 million at December 31.Estimates cash resources are sufficient to fund operations through Q1 2020​.Qtrly loss per share $1.86‍​.Q3 earnings per share view $-1.78 -- Thomson Reuters I/B/E/S.  Full Article

Esperion announces initiation of pivotal late stage study for bempedoic acid
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Esperion Therapeutics Inc :Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill.Esperion Therapeutics - ‍NDA submission for LDL-C lowering indication for bempedoic acid / ezetimibe combination pill expected by Q1 2019​.Esperion Therapeutics Inc - ‍top-line results expected by q4 of 2018 for bempedoic acid / ezetimibe combination pill​.  Full Article

Meditor Group Ltd reports 8.2 pct passive stake in Esperion Therapeutics Inc
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Esperion Therapeutics Inc ::Meditor Group Ltd reports 8.2 percent passive stake in Esperion Therapeutics Inc as on Aug 10 - SEC filing​.  Full Article

Why U.S. small caps may lag despite U.S.-China trade truce

NEW YORK, July 1 A truce in the trade war between the United States and China that pushed large-cap stocks to new record highs Monday does not appear to be enough to buoy the shares of small U.S. companies that are struggling under the weight of higher tariff costs.